Skip to main content
. 2014 Spring;2(1):19–23.

Table 3.

Relative sensitivity for prostate cancer of FDG-PET and of other screening test, according to clinical and pathological UICC stage.

Subject Stage Sensitivity
FDG-PET Pelvic MRI PSA
Clinical and Pathological stage II or less 31.5 (17/54) 62.5 (15/24) 90.4 (47/52)
III 22.2 (2/9) 100.0 (5/5) 100.0 (8/8)
IV 80.0 (4/5) 100.0 (2/2) 66.7 (2/3)

UICC: Union for International Cancer Control